EMA Committee recommends EU label update for Roche Phesgo to allow administration outside of clinical settings Ruchika Sharma4 May 2025 1:30 PM ISTBasel: Roche has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive...
Aurobindo Pharma arm CuraTeQ Biologics gets positive opinion for breast cancer drug Dazublys from EMA Ruchika Sharma26 April 2025 11:30 AM ISTHyderabad: CuraTeQ Biologics s.r.o., a wholly owned step-down subsidiary of Aurobindo Pharma Limited, has announced that the Committee for...
Biocon Biologics, Sandoz Australia ink pact for biosimilars Trastuzumab, Bevacizumab Ruchika Sharma9 Feb 2024 12:30 PM ISTTrastuzumab is a biosimilar of Herceptin and Bevacizumab is a biosimilar of Avastin - both biosimilars are available on the PBS and utilised for the...
Breast cancer biosimilar product meets primary endpoint in Phase 3 clinical trial: Aurobindo Pharma Ruchika Sharma5 July 2023 11:30 AM ISTHyderabad:Aurobindo Pharma Limited has announced that the breast cancer biosimilar product, BP02 (Trastuzumab or biosimilar to Herceptin), developed ...
Roche Holding plans to sell 800-employee drug manufacturing plant in Vacaville Ruchika Sharma4 Jun 2023 12:00 PM ISTThe company said it is seeking a buyer that will continue to use the plant as an operating facility.
FIRST: Roche Pharma unveils DCGI approved PHESGO to treat HER-2 positive breast cancer in India Ruchika Sharma13 May 2022 12:59 PM ISTPHESGO can help breast cancer patients continue receiving their treatment due to significantly shorter administration times and convenience of...
Dr Reddys, Prestige BioPharma ink pact for Trastuzumab biosimilar commercialization in select countries Ruchika Sharma10 Dec 2021 1:24 PM ISTSingapore: Prestige BioPharma Ltd. and Dr. Reddy's Laboratories Ltd. have announced that the two companies have entered into a binding agreement for...
Roche gets European Commission nod for Phesgo to treat HER2-positive breast cancer Ruchika Sharma27 Dec 2020 9:15 AM ISTPhesgo is available as a single-dose vial for SC injection and enables over 90% faster treatment than IV administration of standard of care therapy...
